Is Zelsuvmi still hard to find in 2026? Get the latest update on Zelsuvmi availability, pricing, insurance coverage, and what patients can do right now.
If you've been trying to get Zelsuvmi (berdazimer) for your molluscum contagiosum, you already know the journey hasn't been smooth. Between the delayed launch, limited pharmacy availability, and insurance hurdles, patients have had a frustrating time accessing this breakthrough medication.
Here's where things stand in 2026 — and what you can do about it.
As of early 2026, Zelsuvmi is not listed on the FDA's drug shortage database. That means there isn't an official supply shortage. However, many patients still struggle to find it at their local pharmacy. The issue isn't a manufacturing shortage — it's a distribution and access problem.
Zelsuvmi launched commercially in July 2025, more than 18 months after its FDA approval in January 2024. That delay was caused by licensing and commercialization transitions — the drug went from Ligand Pharmaceuticals to Pelthos Therapeutics through a merger with Channel Therapeutics. During that long gap, pharmacies had no product to stock, and no distribution infrastructure was in place.
Now the product is available, but many pharmacies — especially smaller chains and independents — still don't routinely stock it. The combination of high cost (around $2,350 per kit), refrigeration requirements, and relatively niche demand means pharmacies are cautious about keeping inventory.
Several factors continue to make Zelsuvmi harder to find than most prescriptions:
For a deeper look at all the reasons behind the difficulty, see our article: Why is Zelsuvmi so hard to find?
Here's what you can expect to pay:
There is no generic version of Zelsuvmi available, and none is expected in the near future. For a detailed cost breakdown and savings strategies, see: How to save money on Zelsuvmi.
The access landscape for Zelsuvmi is improving, even if slowly:
Pelthos is also expanding its dermatology portfolio, having acquired Xepi and Xeglyze in late 2025, which signals a long-term commitment to the dermatology market and Zelsuvmi's distribution infrastructure.
If you need Zelsuvmi today, here are your best steps:
For a full toolkit of strategies, read: How to find Zelsuvmi in stock near you.
If you need treatment now and can't access Zelsuvmi, there are effective alternatives. Ycanth (cantharidin) is another FDA-approved treatment for molluscum contagiosum that's applied in a dermatologist's office. Cryotherapy and curettage are widely available in-office procedures. And imiquimod cream is available as an off-label at-home option.
See our complete guide: Alternatives to Zelsuvmi if you can't fill your prescription.
Zelsuvmi isn't technically in shortage — but for many patients, it can still feel that way. The distribution challenges are real, but the situation is meaningfully better than it was a year ago, and access continues to expand with new insurance coverage and distribution partnerships.
If you're struggling to find Zelsuvmi, don't give up. Use Medfinder to search for availability, explore home delivery, and take advantage of the ZelsuvmiGO support program. Help is available — you just need to know where to look.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
